总生存期-话题@MedSci

#总生存期#

65篇内容 | 4094人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1516018, encodeId=b8051516018b4, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=86, createdTime=2019-07-27, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516017, encodeId=0f66151601e52, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, objectType=article, longId=155723, objectId=f948155e2338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f948155e2338, replyNumber=0, likeNumber=79, createdTime=2018-12-15, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f948155e2338, moduleTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f948155e2338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516016, encodeId=15141516016de, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Ann Oncol：G-CSF+化疗可显著改善癌症患者的总生存期？, objectType=article, longId=152047, objectId=682715204e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=682715204e1c, replyNumber=0, likeNumber=129, createdTime=2018-10-29, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=682715204e1c, moduleTitle=Ann Oncol：G-CSF+化疗可显著改善癌症患者的总生存期？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=682715204e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516015, encodeId=7b6a15160153f, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, objectType=article, longId=151769, objectId=5ffc151e69a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ffc151e69a2, replyNumber=0, likeNumber=82, createdTime=2018-10-25, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ffc151e69a2, moduleTitle=NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ffc151e69a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516014, encodeId=6f8e151601494, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, objectType=article, longId=149667, objectId=310b14966e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310b14966e82, replyNumber=0, likeNumber=83, createdTime=2018-09-28, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310b14966e82, moduleTitle=NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310b14966e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516013, encodeId=8ff1151601331, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, objectType=article, longId=148716, objectId=1eac148e167e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eac148e167e, replyNumber=0, likeNumber=94, createdTime=2018-09-14, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eac148e167e, moduleTitle=Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1eac148e167e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516012, encodeId=b9d0151601202, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, objectType=article, longId=136870, objectId=65ff1368e0d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff1368e0d9, replyNumber=0, likeNumber=69, createdTime=2018-05-01, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff1368e0d9, moduleTitle=Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff1368e0d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516011, encodeId=bd1c1516011e7, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期, objectType=article, longId=122135, objectId=146112213524, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=146112213524, replyNumber=0, likeNumber=85, createdTime=2017-12-04, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=146112213524, moduleTitle=2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=146112213524)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516010, encodeId=87c115160103b, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Br J Cancer：疾病进展时间和肝癌总生存期有什么联系？, objectType=article, longId=80609, objectId=15f480609e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15f480609e8, replyNumber=0, likeNumber=91, createdTime=2016-10-22, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15f480609e8, moduleTitle=Br J Cancer：疾病进展时间和肝癌总生存期有什么联系？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15f480609e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516009, encodeId=c91c15160093d, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期, objectType=article, longId=79706, objectId=03fbe9706d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fbe9706d9, replyNumber=0, likeNumber=81, createdTime=2016-10-12, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fbe9706d9, moduleTitle=NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fbe9706d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516008, encodeId=861715160085a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, objectType=article, longId=79623, objectId=aa97e962349, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa97e962349, replyNumber=0, likeNumber=79, createdTime=2016-10-11, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa97e962349, moduleTitle=ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa97e962349)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516007, encodeId=ea57151600efe, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=JCO：血浆维生素D水平能预测胰腺癌患者的总生存期, objectType=article, longId=71796, objectId=1c14e1796aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c14e1796aa, replyNumber=0, likeNumber=45, createdTime=2016-06-30, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c14e1796aa, moduleTitle=JCO：血浆维生素D水平能预测胰腺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c14e1796aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516006, encodeId=fbbc15160068b, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, objectType=article, longId=71400, objectId=0e3be140052, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e3be140052, replyNumber=0, likeNumber=83, createdTime=2016-06-23, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e3be140052, moduleTitle=默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e3be140052)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516005, encodeId=cf3b151600515, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet：eribulin可显著晚期软组织肉瘤患者总生存期, objectType=article, longId=63154, objectId=eb0463154a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb0463154a9, replyNumber=0, likeNumber=61, createdTime=2016-02-13, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb0463154a9, moduleTitle=Lancet：eribulin可显著晚期软组织肉瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb0463154a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516004, encodeId=c13215160042e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期, objectType=article, longId=60984, objectId=7d006098472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d006098472, replyNumber=0, likeNumber=110, createdTime=2015-12-23, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d006098472, moduleTitle=Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d006098472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516003, encodeId=06b215160032a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期, objectType=article, longId=58057, objectId=317e5805e9d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317e5805e9d, replyNumber=0, likeNumber=89, createdTime=2015-10-31, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317e5805e9d, moduleTitle=ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=317e5805e9d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516002, encodeId=93f715160028f, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值, objectType=article, longId=56519, objectId=63bc5651986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63bc5651986, replyNumber=0, likeNumber=53, createdTime=2015-09-25, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63bc5651986, moduleTitle=Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63bc5651986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516001, encodeId=9a6f1516001bf, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期, objectType=article, longId=54560, objectId=d5ed54560fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5ed54560fc, replyNumber=0, likeNumber=75, createdTime=2015-08-08, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5ed54560fc, moduleTitle=Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5ed54560fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516000, encodeId=e76f151600041, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期, objectType=article, longId=54489, objectId=7cf754489be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cf754489be, replyNumber=0, likeNumber=82, createdTime=2015-08-07, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cf754489be, moduleTitle=NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cf754489be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515999, encodeId=b2921515999bf, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), objectType=article, longId=54327, objectId=0ab65432efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab65432efa, replyNumber=0, likeNumber=66, createdTime=2015-08-03, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab65432efa, moduleTitle=Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab65432efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

总生存期

2020-05-29

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2019-07-27

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

2018-12-15

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Ann Oncol：G-CSF+化疗可显著改善癌症患者的总生存期？

2018-10-29

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：免疫治疗在晚期三阴乳腺癌III期临床试验中成功！中位总生存期提高61.3%

2018-10-25

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：Durvalumab可显著延长III期非小细胞肺癌患者总生存期

2018-09-28

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet Oncol：曲妥珠单抗+帕妥珠单抗+化疗不能延长HER2阳性转移性胃或胃食管交界癌患者总生存期

2018-09-14

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Cabozantinib与舒尼替尼作为中度或低风险转移性肾细胞癌的最佳治疗方案（Alliance A031203 CABOSUN随机试验）：总生存期和无进展生存

2018-05-01

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

2017ASH前瞻：白血病组合疗法显疗效显著提高总生存期

2017-12-04

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Br J Cancer：疾病进展时间和肝癌总生存期有什么联系？

2016-10-22

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：Nivolumab可延长复发性头颈鳞状细胞癌患者的总生存期

2016-10-12

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ESMO 2016：奥拉帕尼能否改善胃癌患者的总生存期？（GOLD试验）

2016-10-11

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

JCO：血浆维生素D水平能预测胰腺癌患者的总生存期

2016-06-30

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

默沙东PD-1免疫疗法Keytruda一线治疗晚期非小细胞肺癌（NSCLC）显著延长总生存期和无进展生存期

2016-06-23

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet：eribulin可显著晚期软组织肉瘤患者总生存期

2016-02-13

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet：恶性胸膜间皮瘤——贝伐单抗可显著改善总生存期

2015-12-23

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ASA 2015：治疗便秘药物Relistor可延长癌症患者总生存期

2015-10-31

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet Oncol：疲劳评估对骨髓增生异常综合征等患者的总生存期有预后价值

2015-09-25

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet Oncol：新辅助化放疗加手术可提高食管和交界癌患者的总生存期

2015-08-08

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期

2015-08-07

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Ann Oncol：厄洛替尼对比化疗一线治疗对EGFR突变NSCLC患者总生存期影响 (OPTIMAL, CTONG-0802研究)

2015-08-03

科室
- - 订阅+
  - 更多科室
工具
服务